跳至主要内容
临床试验/NCT03011957
NCT03011957Unknown不适用

Biomarkers for Muscle Function and Aging in Chronic HIV Infection

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2015年2月最近更新:
适应症

试验速览

阶段
不适用
入组人数
160
试验地点
1
主要终点
Inflammation at baseline and 3 years

研究概览

简要总结

MATCH is an observation study of HIV-infected adults on effective antiretroviral therapy (ART) and demographically matched uninfected adults to evaluate muscle and aging.

详细描述

MATCH is a non-randomized observational longitudinal study. We will recruit HIV infected adults (50 to 65 years old) and demographically matched uninfected control subjects to be followed for 4 years over the course of a 5 year study. The targeted age range of 50-65 is chosen to evaluate aging HIV infected individuals at risk for early frailty in the United States. All subjects will undergo blood draws and physical function assessment, and a subset will undergo a CT scan of muscle and will have a muscle biopsy taken.

A substudy will be performed on a subgroup of HIV-infected and HIV-uninfected men from the main cohort to measure daily physical activity by using an activity tracker.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
50 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Group 1: HIV positive subjects
  • HIV positive
  • English speaking
  • 50-65 years old
  • On Antiretroviral therapy and an HIV viral load below 200 copies/ml
  • CD4 equal to or greater than 350 cells/mm3
  • Postmenopausal (women)
  • Lower extremity mobility sufficient to participate in functional assessment.
  • Group 2: HIV negative subjects Inclusion Criteria for Group 2 subjects
  • English speaking
  • 50-65 years old
  • Negative for HIV (based on an HIV antibody test at Study Visit 1)
  • Matched to Group 1 for sex (50% W, 50% M) and age (50 - 65yo)
  • Postmenopausal (women)
  • Lower extremity mobility sufficient to participate in functional assessment.

排除标准

  • Exclusion Criteria for Group 1 Subjects
  • Acute or serious illness within 60 days prior to entry
  • Use of pharmacologic doses of corticosteroids in the past 6 months.
  • Use of anabolic therapy in the past 6 months.
  • Lower extremity mobility insufficient to participate in functional assessment.
  • Current use (last 30 days) of anticoagulants or known bleeding disorder.
  • Exclusion Criteria for Group 2 subjects
  • Acute or serious illness within 60 days prior to entry
  • Use of pharmacologic doses of corticosteroids in the past 6 months
  • Use of anabolic therapy in the past 6 months
  • Lower extremity mobility insufficient to participate in functional assessment
  • Current use (last 30 days) of anticoagulants or known bleeding disorder.

结局指标

主要结局

Inflammation at baseline and 3 years

时间窗: 3 years

Inflammation at baseline and yearly for 3 years will be assessed by measuring circulating levels of inflammatory cytokines (e.g., CRP, IL6) and soluble monocyte/macrophage biomarkers (e.g., sCD14, sC163). These multiple measurements will be aggregated to arrive at one composite inflammatory score. Outcome will be assessed in association with HIV status and physical function.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Monty Montano

Director, Muscle and Aging Interventions

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验